Christine Cripps

Final clinical and pharmacokinetic (PK) results from a phase 1 study of the novel N-cadherin (N-cad) antagonist, Exherin (ADH-1), in patients with refractory solid tumors stratified according to N-cad expression.

D. Jonker, G. Goss, J. Maroun, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.